01Acrivon Therapeutics reported Q3 2026 earnings per share of -$0.42, beating estimates by $0.02 but revenue missed projections.
02The company's stock trades at $1.43 with a market capitalization of $47.6 million as of the earnings release.
03Acrivon has beaten earnings estimates in three of the last four quarters, with the largest beat of 14.0% in Q2 2026.
04The company continues to report negative earnings, with losses narrowing from -$0.49 in Q1 2026 to -$0.42 in Q3 2026.
Earnings Results
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly earnings results on November 16, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.42, beating the consensus estimate of $-0.44 by $0.02 per share. Revenue came in at , missing the estimate of $606.0K.
Company Overview
Acrivon Therapeutics's stock moved following the earnings release. The stock currently trades at $1.43 with a market capitalization of $47.6M.
Acrivon Therapeutics's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Acrivon Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.